Why the study?
Does pre-implant GDF-15 predict mortality and morbidity in heart failure patients undergoing cardiac resynchronization therapy?
Does pre-implant GDF-15 predict mortality and morbidity in heart failure patients undergoing cardiac resynchronization therapy?
Pre-implant GDF-15 is a strong, independent predictor of mortality and morbidity in heart failure patients undergoing cardiac resynchronization therapy, and its predictive value is enhanced when combined with NT-proBNP.
No takes yet. Share an insight, caveat, or question.
GDF-15 may refine risk stratification before CRT; leaves open whether it improves decision-making beyond NT-proBNP in prospective studies.
Foley et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: